HCW Biologics is trading at $3.16, down 5.81% during the open session, with no new negative company-specific catalyst or explicit explanation identified for the September 3 decline.
- September 2 closed at $3.35, down 2.75%.
- Broader biotechnology sector is rising, so sector weakness does not explain the drop.
- Latest announcement was a positive USPTO Notice of Allowance covering HCW9302’s alopecia areata use and four additional patents.